EP1328552A4 - Vernetzte amidderivate der hyaluronsäure und herstellungsverfahren dafür - Google Patents

Vernetzte amidderivate der hyaluronsäure und herstellungsverfahren dafür

Info

Publication number
EP1328552A4
EP1328552A4 EP01974948A EP01974948A EP1328552A4 EP 1328552 A4 EP1328552 A4 EP 1328552A4 EP 01974948 A EP01974948 A EP 01974948A EP 01974948 A EP01974948 A EP 01974948A EP 1328552 A4 EP1328552 A4 EP 1328552A4
Authority
EP
European Patent Office
Prior art keywords
hyaluronic acid
oligomer
amide derivatives
water
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01974948A
Other languages
English (en)
French (fr)
Other versions
EP1328552B1 (de
EP1328552A1 (de
Inventor
Tae-Seok Moon
Jae-Young Lee
Jin-Hoon Kim
Kyu-Boem Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
Original Assignee
LG Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Life Sciences Ltd filed Critical LG Life Sciences Ltd
Publication of EP1328552A1 publication Critical patent/EP1328552A1/de
Publication of EP1328552A4 publication Critical patent/EP1328552A4/de
Application granted granted Critical
Publication of EP1328552B1 publication Critical patent/EP1328552B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Definitions

  • the present invention relates to crosslinked amide derivatives of hyaluronic acid and manufacturing methods thereof, more particularly, a water-insoluble, crosslinked amide derivatives of hyaluronic acid characterized by crosslinking of polymer or oligomer having two or more amine groups, with hyaluronic acid or its hyaluronate salts through amidation reaction.
  • Hyaluronic acid (hereinafter abbreviated 'HA') is a bio-polymeric material where repeat unit comprising N-acetyl-D-glucosamine and D-glucuronic acid is linearly repeated in connection, which polymer plentifully exists in vitreous humor, synovial fluid, connective tissues etc.
  • ⁇ A' means hyaluronic acid and any of its hyaluronate salts.
  • Hyaluronate salts according to the present invention include but not limited to inorganic salts such as sodium hyaluronate and potassium hyaluronate etc. and organic salts such as tetrabutylammonium hyaluronate etc..
  • Preferable hyaluronate salt of HA according to the present invention is sodium hyaluronate.
  • HA derivatives have been developed in diverse uses for prevention of adhesion after surgical operation, correction of facial wrinkles, dermal augmentation, tissue engineering, osteoarthritic viscosupplement etc..
  • HA derivatives may largely be classified by water solubility into water-soluble derivatives and water-insoluble derivatives.
  • manufacturing methods of those may largely be thought in two ways: one is to react HA with a compound having one functional group to combine this compound with linear chain of HA while the other is to react HA with a compound having two or more functional groups to make - crosslinked HA.
  • Another object of the present invention is to provide manufacturing method of such water-insoluble, crosslinked amide derivatives of HA as above.
  • the present invention relates to crosslinked amide derivatives of HA and manufacturing method thereof.
  • the above derivatives may be those crosslinked through amidation reaction from polymer or oligomer having two or more amine groups and having various molecular weights together with HA having various molecular weights.
  • the above polymer or oligomer may be polycationic polymer or oligomer.
  • Crosslinked amide derivatives of HA according to the present invention are good in viscoelasticity, so they may be applied in diverse uses. Also crosslinked amide derivatives of HA according to the present invention may have characteristics of such as sponge or rubber.
  • the present invention have features that faster reaction rate and higher yield can be obtained by reacting the polycationic polymer or oligomer having two or more amine groups with HA having carboxylate group, so the above polycationic polymer or oligomer and the above HA are close to each other by electrostatic attraction between the amine groups and carboxyl groups.
  • the polycationic polymer or oligomer having two or more amine groups and the HA do not form the ionic bonds but form the covalent bonds by amidation reaction
  • the crosslinked amide derivatives of HA according to the present invention are bio-materials which resist various conditions of living bodies, i.e., high salt concentrations, low pH etc.. And those may be said to be new biomaterials having quite different properties from existing water-insoluble HA derivatives crosslinked by using EDC.
  • water-insoluble, crosslinked amide derivatives of HA are that these are new bio-materials having overcome demerit of existing water-insoluble HA derivatives to be easily decomposed in living body and easily dissolved under harsh condition such as acidic condition etc. as well as these are biologically acceptable material of excellent properties showing high viscoelasticity.
  • the present invention provides water-insoluble, crosslinked amide derivatives of HA in that the polycationic polymer or oligomer having two or more amine groups and HA are crosslinked each other by amidation reaction.
  • the polymer or oligomer having two or more amine groups means that it has two or more amine groups per polymer or oligomer molecule.
  • the present invention provides water-insoluble, crosslinked amide derivatives of HA characterized in that the polymer or oligomer contains amine groups which can accept protons so that have positive charges under acidic or neutral condition and the polymer or oligomer having amine groups reacts with carboxyl groups of HA under the existence of carboxyl group activating agent to produce water-insoluble, crosslinked amide derivatives of HA according to the present invention by promoting the amidation reaction induced by electrostatic attraction between the amine groups of the polymer or oligomer and carboxyl groups of the HA.
  • the present invention provides water-insoluble, crosslinked amide derivatives of HA characterized in that the ratio of the carboxyl groups of the HA versus the amine groups of the polycationic polymer or oligomer is 1:0.01 to 100 in the reaction mixture. More preferably, the present invention provides water-insoluble, crosslinked amide derivatives of HA characterized in that the polymer or oligomer having two or more amine groups reacts with carboxyl group of HA under the existence of carboxyl group activating agent to produce water-insoluble, crosslinked amide derivatives of HA according to the present invention by amidation reaction.
  • the present invention provides water-insoluble, crosslinked amide derivatives of HA characterized in that the amidation reaction is carried out under acidic or neutral condition, the polymer or oligomer is polycationic polymer or oligomer charged positively by protonating the amine group in the polymer or oligomer, so the amine groups of the polycationic polymer or oligomer and the carboxyl group of the HA promote the amidation reaction by using the electrostatic attraction between the amine groups of the polymer or oligomer and carboxyl groups of the HA.
  • the present invention also provides manufacturing method of water-insoluble, crosslinked amide derivatives of HA characterized in that the method comprising a step of reacting polymer or oligomer having two or more amine groups with HA. More preferably, the present invention provides manufacturing method of water-insoluble, crosslinked amide derivatives of HA characterized in that polymer or oligomer having amine groups which can accept protons so that have positive charges under acidic or neutral condition and the amine groups of the polymer or oligomer react with the carboxyl groups of the HA.
  • the present invention provides manufacturing method of water-insoluble, crosslinked amide derivatives of HA characterized in that the ratio of the carboxyl group of the HA versus the amine group of the polymer or oligomer is 1 : 0.01 to 100 in the reaction mixture. More preferably, the present invention provides manufacturing method of water-insoluble, crosslinked amide derivatives of HA characterized in that the amidation reaction is carried out under acidic or neutral condition, the polymer or oligomer is polycationic polymer or oligomer charged positively by protonating the amine group in the polymer or oligomer, so the amine groups of the polymer or oligomer react with the carboxyl groups of the HA.
  • Examples of the above polymer or oligomer having two or more amine groups are natural materials having two or more amine groups, synthetic materials synthesized by using these natural materials, and polymer or oligomer derivatives thereof.
  • the molecular weights of the above polymers are preferably about 3,000 to 10,000,000 while the molecular weights of the above oligomers are about 300 to 3,000.
  • the present invention provides manufacturing method of water-insoluble, crosslinked amide derivatives of HA characterized in that the method comprising steps of : mixing the HA aqueous solution with the polymer or oligomer aqueous solution having two or more amine groups to induce electrostatic attraction between the HA and the polymer or oligomer; reacting the two functional groups existing close to each other, i.e. carboxyl group of the HA and amine group of the polymer or oligomer to produce water-insoluble bio-materials; washing with water and acid solution etc.; isolating the refined material; and drying the material.
  • the manufacturing method according to the present invention has some features of easy reaction, simple separation process and no needs of toxic, organic solvent.
  • Examples of the carboxyl group activating agent added to the amidation reaction to activate the carboxyl group are carbodiimides.
  • the above carbodiimide may be selected from the group comprising compounds easily soluble in water such as EDC (l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride), l-alkyl-3-(3-dimethylaminopropyl) carbodiimides having structure similar to EDC, ETC (l-ethyl-3-(3-(trimethylammonio)propyl) carbodiimide), CMC
  • auxiliary agent to the above amidation reaction may be added optionally.
  • Materials soluble in water, capable of forming active ester, may all be used as auxiliary agent to the above amidation reaction.
  • the auxiliary agent may be selected from the group comprising NHS (N-hydroxysuccinimide), HOBt (1-hydroxybenzotriazole), HOOBt (3,4-dihydro-3-hydroxy-4-oxo-l,2,3-benzo triazine), HOAt (l-hydroxy-7-azabenzotriazole), Sulfo-NHS (N-hydroxysulfosuccinimide) etc.
  • EDC may be added in 0.0001 to 100 ing and
  • NHS may be added in 0 to 100 ⁇ g/m& in the preferable examples of the present invention.
  • the molecular weight of HA used for crosslinked amide derivatives of HA and manufacturing method thereof according to the present invention may be 10,000 to 10,000,000 and the concentration of HA may be 0.01 to 100 mg .
  • the polymer or oligomer having two or more amine groups in the manufacturing method according to the present invention may be selected from the group comprising chitosan, chitosan derivatives, deacetylated HA, deacetylated HA derivatives, polyethylene glycol or protein or peptide having two or more reactable amine groups which can accept proton, etc.
  • the polymer or oligomer having two or more amine groups used for the crosslinked amide derivatives of HA and its manufacturing method according to the present invention may be substance soluble in aqueous solution of pH 2 to 8.
  • the solvent using in the amidation reaction according to the present invention may be water, aqueous buffer solution, etc. but not limited to these. It is preferable that the temperature of the amidation reaction according to the present invention is 0 to 40°C, and more particularly room temperature. It is preferable that the pH of the amidation reaction according to the present invention may be 2 to 8, and more particularly 4 to 6.
  • the amidation reaction time according to the present invention is 0.5 to 20 hours, more particularly about 2 hours.
  • Water-insoluble, crosslinked amide derivatives of HA according to the present invention may be made to have form of gel, membrane, bead, mesh, etc..
  • product may be separated and/or refined from the reaction system according to usual method l ⁇ iown to the art.
  • separation and/or refinement may be selected from distillation under atmospheric or vacuum distillation, recrystallization, column chromatography, ion exchange chromatography, gel chromatography, affinity chromatography, thin layer chromatography, phase separation, solvent extraction, washing, etc..
  • Refining may be carried out after each reaction or a series of reaction.
  • the reagents and the start materials required for the amide derivative synthesis according to the present invention may either be easily prepared by the methods disclosed in the known literature, above-described methods or be purchased from many manufacturers all over the world.
  • Fig. 1 is a spectrum of infrared spectroscopy for Sample A of Table 2 in example 3.
  • Fig. 2 is a spectrum of infrared spectroscopy for Sample B of Table 2 in example 3.
  • Fig. 3 is a spectrum of infrared spectroscopy for Sample C of Table 2 in example s.
  • Fig. 4 is a spectrum of infrared spectroscopy for Sample D of Table 2 in example 3.
  • Fig. 5 is diagrammatic presentation of structure and synthesis procedure for hyaluronic acid derivative crosslinked with chitosan.
  • Example 1 preparation of amide derivatives of HA crosslinked with chitosan
  • aqueous solution of sodium hyaluronate (mol. wt. > 2,000,000) and 0.625 mg/ml of aqueous solution of chitosan-HCl were prepared.
  • the above aqueous solution of chitosan-HCl was added while the above aqueous solution of sodium hyaluronate was being stirred.
  • Chitosan-hyaluronate was precipitated after the aqueous solution of chitosan-HCl had been added. pH became 4 to 5 after complete mixing of the two solutions.
  • EDC and NHS were slowly added to the above mixed solution with concentrations according to the following Table 1 while stirring well. Reaction was carried out for two hours at 25 °C after this addition.
  • the sample not added of EDC and NHS in Table 1, namely, the sample where chitosan and HA have been precipitated in form of ionic bond, may be dissolved in water under condition of high salt concentration or low pH.
  • IN HC1 was added slowly to the above mixed solution until this sample (group A in Table 1) is completely dissolved. About 30 min. were required for this addition where about 3 ml of 1 N HC1 was required for the above mixed solution 100 ml to be dissolved completely.
  • Remainder samples (added of EDC and NHS, groups B, C, D, and E in Table 1) were also treated under same condition, and unreacted chitosan and HA which were simply precipitated in ionic bond form were removed from the amide derivatives of HA crosslinked with chitosan through amidation reaction. Remainder part not dissolved even after the above acid treatment was washed with abundant water to completely remove unreacted EDC or NHS and by-products of these after which this remaining portion was vacuum dried at 25°C. Water-insoluble, amide derivatives of HA crosslinked with chitosan could be obtained through the above procedure. The more EDC and NHS were added for the reaction, the larger quantity of final product could be obtained.
  • Example 2 preparation of amide derivatives of HA crosslinked with chitosan
  • Example 3 a test of resistance to acid and high salt concentration and a confirmation of amide formation in the amide derivatives of HA crosslinked with chitosan
  • Opaque small particles have not been dissolved but are dispersed in whole
  • Bioactive & Compatible Polymers, 9, 429-447 (1994)) coincides with the fact that material according to the present invention has been crosslinked as shown by the test of resistance to acid and high salt concentration. These data confirm that these derivatives of HA according to the present invention have been crosslinked by amide formation. Formation of ester (1745 to 1760cm “1 ) or anhydride of carboxylic acid (1800cm “1 ), which can occur as side reaction was not observed on spectrums (Silverstein et al., Spectrometric Identification of Organic Compounds, pp. 122 to 124, John Wiley and Sons, New York (1981)). Formation of N-acylurea (1700cm "1 ) that is a by-product that may be made when using EDC was not also observed on spectrums (see U.S. Patent 5,527,893).
  • Fig. 5 diagrammatically shows the structure of amide derivatives of HA crosslinked with chitosan and its synthesis procedure by summarizing the above spectral analysis result and the above test result of resistance to acid and high salt concentration.
  • Example 4 preparation of crosslinked amide derivatives of HA by using deacetylated HA
  • HA solution If the temperature of HA solution is raised under high or low pH condition, deacetylation is progressed along with chain decomposition so as to form quite an active amine.
  • This amine may form amide bond with carboxyl group by the same chemistry as that of chitosan in Example 1 or 2.
  • Reaction was carried out for 1 to 30 hours at 25 to 50°C with HA by using 0.2 to ION NaOH (aq.) in order to deacetylate HA. Reaction was terminated by neutralization with HC1 after which deacetylated HA was obtained by freeze-drying after dialysis. Degree of deacetylation was determined after measuring quantity of amine group formed as the result of reaction by using Roth's fluorimetric method (see Anal. Chem., 1971, 43, 880 to 882; J. Chromatogr., 1973, 83, 353 to 356; Clin. Chem. Clin. Biochem., 1976, 14, 361 to 364). Degree of deacetylation was calculated from the following equation.
  • HA] x 100 (%) Concentration of repeat units of HA was obtained by quantifying carboxyl group according to the presumption that a carboxyl group exists per repeat unit of HA. Carboxyl group quantification was done by carbazole method (Anal. Biochem., 1962, 4, 330). Degree of deacetylation became 1 to 40% as the result of reaction. The amidation reaction was carried out using deacetylated HA obtained by the above method. EDC (2.4mg ) and NHS (2.9mg ) were added into deacetylated HA (lOmg/ mi), which was reacted for 2 hours at 25 °C , then the derivatives formed were refined and vacuum dried. Water-insoluble gel was formed in yield of 51%.
  • Example 5 preparation of amide derivatives of HA crosslinked with deacetylated HA
  • Example 6 manufacturing membrane made of amide derivatives of HA crosslinked with chitosan
  • Example 7 manufacturing membrane made of amide derivatives of HA crosslinked with chitosan
  • aqueous solution of sodium hyaluronate (mol. wt. ⁇ 2,000,000) and 0.625mg/m& of aqueous solution of chitosan-HCl were prepared.
  • the above aqueous solution of sodium hyaluronate was poured into glass plate, and then EDC and NHS were added to the above aqueous solution of sodium hyaluronate in various concentrations of such as Groups B, C, D and E of Table 1. After they were well mixed, the above aqueous solution of chitosan-HCl was added to the plate to produce white membrane in the plate.
  • Example 8 manufacturing bead made of amide derivatives of HA crosslinked with chitosan
  • a dried, amide derivatives of HA according to the above example 1 were finely ground and dispersed in water or physiological saline etc.. It became bead solution of amide derivatives of HA injectable by syringe.
  • Example 9 manufacturing bead made of amide derivatives of HA crosslinked with chitosan
  • a dried, amide derivatives of HA according to the above example 2 were finely ground and dispersed in water or physiological saline etc.. It became bead solution of amide derivatives of HA injectable by syringe.
  • Example 10 preparing a hydrated gel made of amide derivatives of HA crosslinked with chitosan
  • modulus values are in range similar to that of rubber. This result coincides with the fact that the material according to the present invention is crosslinked substance and thus shows that this material may be used as implant for dermal augmentation etc.
  • high storage modulus means high elasticity while high loss modulus means high viscosity.
  • Amide derivatives of HA of hydrated gel type having high viscoelasticity could be made by method as above.
  • Example 11 preparing hydrated gel made of amide derivatives of HA crosslinked with chitosan
  • Loss modulus at frequency 0.01 to 0.1 Hz 10 to 50 kPa
  • the hydrated gel made of amide derivatives of HA having high viscoelasticity could be made by method as above.
  • Example 12 preparing crosslinked amide derivatives of various material properties according to mol. wt. and concentrations of HA and chitosan and concentrations of EDC and NHS
  • Crosslinked amide derivatives of HA with various material properties could be prepared by combining a variety of the following parameters:
  • Mol. wt. of sodium hyaluronate lower than 300,000; 300,000 to 3,000,000; higher than 3,000,000
  • HA cone (mg/ml) : 0.02, 0.1, 1.0, 10, and 80 Mol. wt. of chitosan represented by viscosity value of aqueous solution of chitosan (viscosity measured by Brookfield viscometer where chitosan was dissolved to be 1 % cone, in aqueous solution of 1 % acetic acid): low mol. wt. (20 to 200 cps); medium mol. wt. (200 to 800 cps): high mol. wt. (800 to 2000 cps) Chitosan cone, (mg/ml) : 0.005, 0.01, 0.05, 0.1, 0.5, 1.0, 5.0, 10, 20, 40, and 80
  • EDC cone (mg/ml) : 0.00096, 0.0048, 0.0096, 0.024, 0.048, 0.24, 0.48, 2.4, 3.84, 4.8, 19.2, 38.4, and 76.8
  • NHS cone (mg/ml) : 0, 0.000576, 0.001152, 0.001728, 0.00288, 0.00576, 0.00864, 0.01152, 0.0144, 0.01728, 0.0288, 0.0432, 0.0576, 0.0864, 0.144, 0.288, 0.432, 0.576, 0.864, 1.44, 2.304, 2.88, 4.32, 4.608, 5.76, 6.912, 8.64, 11.52, 23.04, 34.56, 46.08, 69.12, and 92.16 •
  • Hydrated gel type amide derivatives of HA could be made as described in Example 10 using the obtained amide derivatives of HA crosslinked with chitosan. The following measurement values could be obtained as the result of measurement of rheological properties of this gel containing water by using rheometer.
  • Loss modulus at frequency 0.01 to 0.1 Hz 2 to 60 kPa
  • crosslinked amide derivatives of HA according to the present invention is very excellent in viscoelasticity, it is applicable in various uses.
  • the crosslinked amide derivatives of HA according to the invention may be diversely used for prevention of adhesion after surgical operation, correction of facial wrinkles, dermal augmentation, tissue engineering, osteoarthritic viscosupplement etc.
  • the present invention have features that faster reaction rate and higher yield can be obtained by reacting the polycationic polymer or oligomer having two or more amine groups and the above HA, which are close to each other by electrostatic attraction between the amine group and carboxyl group. Because the polycationic polymer or oligomer having two or more amine groups and the HA do not form the ionic bonds but form the covalent bonds by amidation reaction, the crosslinked amide derivatives of HA according to the present invention are bio-materials which resist conditions of living bodies, i.e., high salt concentrations, low pH etc.. And those may be said to be new biomaterials having quite different properties from existing water-insoluble materials through HA crosslinked by using EDC.
  • water-insoluble, crosslinked amide derivatives of HA are that these are new bio-materials having overcome demerit of existing HA derivatives to be easily decomposed in living body and easily dissolved under harsh condition such as acidic condition etc. as well as these are biologically acceptable material of .excellent property showing high viscoelasticity.
  • the present invention provides manufacturing method of water-insoluble, crosslinked amide derivatives of HA characterized in the method comprising steps of; mixing the HA aqueous solution with the polymer or oligomer aqueous solution having two or more amine groups to induce electrostatic attraction between the HA and the polymer or oligomer; reacting the two functional groups existing close to each other, i.e.
  • the manufacturing method according to the present invention has some features of easy reaction, simple separation process and no needs of toxic, organic solvent. Whereas present invention has been minutely explained as above highlighting concrete examples described above, it is manifest to this enterpriser that their various transformations-modifications are possible within category of present invention and within range of its techn(olog)ical philosophy and so it is also fair-proper that such transformations -modifications belong to range of my appended patent claim.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP01974948A 2000-10-10 2001-10-10 Vernetzte amidderivate der hyaluronsäure und herstellungsverfahren dafür Expired - Lifetime EP1328552B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR2000059443 2000-10-10
KR10-2000-0059443A KR100375299B1 (ko) 2000-10-10 2000-10-10 히알루론산의 가교결합형 아마이드 유도체와 이의 제조방법
PCT/KR2001/001687 WO2002030990A1 (en) 2000-10-10 2001-10-10 Crosslinked amide derivatives of hyaluronic acid and manufacturing method thereof

Publications (3)

Publication Number Publication Date
EP1328552A1 EP1328552A1 (de) 2003-07-23
EP1328552A4 true EP1328552A4 (de) 2005-11-09
EP1328552B1 EP1328552B1 (de) 2012-12-12

Family

ID=19692693

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01974948A Expired - Lifetime EP1328552B1 (de) 2000-10-10 2001-10-10 Vernetzte amidderivate der hyaluronsäure und herstellungsverfahren dafür

Country Status (8)

Country Link
US (1) US6903199B2 (de)
EP (1) EP1328552B1 (de)
JP (1) JP4230767B2 (de)
KR (1) KR100375299B1 (de)
CN (1) CN1290869C (de)
AU (1) AU2001294320A1 (de)
BR (1) BR0114561A (de)
WO (1) WO2002030990A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
KR20040009891A (ko) * 2002-07-26 2004-01-31 주식회사 엘지생명과학 히알루론산의 유도체 겔 및 그 제조방법
KR100523953B1 (ko) * 2002-08-27 2005-10-25 주식회사 엘지생명과학 천연다당류와 히알루론산의 마이크로비드 및 이의 제조 방법
KR100507545B1 (ko) * 2002-09-03 2005-08-09 주식회사 엘지생명과학 히알루론산 유도체 및 그의 제조방법
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
CA2559520A1 (en) * 2004-03-17 2005-09-29 Genzyme Corporation Anti-adhesion spraying
ES2246695B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
ITPD20050056A1 (it) 2005-03-02 2006-09-03 Fidia Farmaceutici Derivati ammidici del'acido ialuronico in osteoartrosi
KR100737954B1 (ko) * 2006-01-03 2007-07-13 고려대학교 산학협력단 조직재생을 위한 히알루론산-기초된 주사형 하이드로겔
US7674781B2 (en) * 2006-04-28 2010-03-09 Heather Sheardown Hyaluronic acid-retaining polymers
WO2008014787A1 (en) * 2006-08-04 2008-02-07 Novozymes Biopolymer A/S Branched hyaluronic acid and method of manufacture
US8043773B2 (en) 2006-11-16 2011-10-25 Ricoh Company, Limited Image bearing member, image forming apparatus and process cartridge
JP5006164B2 (ja) 2006-11-21 2012-08-22 株式会社リコー 画像形成装置、画像形成方法及びプロセスカートリッジ
US20080293637A1 (en) * 2007-05-23 2008-11-27 Allergan, Inc. Cross-linked collagen and uses thereof
US8148038B2 (en) 2007-07-02 2012-04-03 Ricoh Company, Ltd. Image bearing member, process cartridge, image forming apparatus and method of forming image bearing member
US20110077737A1 (en) * 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
BRPI0819075A2 (pt) 2007-11-16 2014-10-07 Vicept Therapeutics Inc Método para tratar púrpura em um indivíduo e método para diminuir a púrpura em um indivíduo antes de um procedimento cirúrgico
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
KR101008595B1 (ko) * 2008-05-16 2011-01-17 고형배 스크린 골프 연습 시스템
WO2009148985A2 (en) * 2008-06-03 2009-12-10 E. I. Du Pont De Nemours And Company A tissue coating for preventing undesired tissue-to-tissue adhesions
US8450475B2 (en) 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
EP3184552B1 (de) 2008-09-02 2020-08-12 Tautona Group LP Stränge aus hyaluronsäure, verfahren zur herstellung davon und verwendungen davon
JP5646507B2 (ja) 2009-01-13 2014-12-24 ペルガムム・エイビーＰｅｒｇａｍｕｍ ＡＢ 創傷、傷跡、および手術後の癒着形成を治療するためのヒアルロン酸含有組成物
EP2413894B1 (de) * 2009-04-02 2017-01-04 Allergan, Inc. Haarartige geformte hydrogele zur verstärkung von weichteilen
KR101047510B1 (ko) * 2009-04-07 2011-07-08 (주)다림티센 에스터화 아텔로콜라겐과 히알루론산을 이용한 유착 방지제 제조방법
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
NZ602405A (en) 2010-03-12 2014-12-24 Allergan Ind Sas A fluid composition comprising a hyaluronan polymer and mannitol for improving skin conditions
AU2011229730B2 (en) 2010-03-22 2016-01-07 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
KR101047512B1 (ko) * 2011-04-20 2011-07-08 (주)다림티센 에스터화 아텔로콜라겐과 히알루론산을 이용한 유착 방지제 제조방법
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
EP3536307B1 (de) 2011-06-03 2021-10-20 ALLERGAN Industrie, SAS Dermale füllstoffzusammensetzungen mit antioxidantien
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
TW201322988A (zh) * 2011-09-08 2013-06-16 Shin Poong Pharmaceutical Co 關節炎之治療注射劑
US9480747B2 (en) 2012-01-24 2016-11-01 Bvw Holding Ag Class of anti-adhesion hydrogels with healing aspects
CN102793952B (zh) * 2012-08-20 2013-11-13 山东省立医院 防止肠粘连的凝胶材料
US9468683B2 (en) 2012-08-28 2016-10-18 University Of Geneva Hybrid hydrogels
FR2997014B1 (fr) 2012-10-24 2015-03-20 Teoxane Composition sterile dermo-injectable
US20140315828A1 (en) 2013-04-22 2014-10-23 Allergan, Inc. Cross-linked silk-hyaluronic acid compositions
CN104208010A (zh) * 2014-08-18 2014-12-17 广州贝奥吉因生物科技有限公司 一种纳米靶向缓控释系统的制备方法
US20160051723A1 (en) * 2014-08-21 2016-02-25 Gregory J. Pomrink Bioresorbable tissue repair composition
EP3200838B1 (de) 2014-09-30 2019-09-18 Allergan Industrie, SAS Stabile hydrogelzusammensetzungen mit additiven
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
CN105381501A (zh) * 2015-12-15 2016-03-09 日照天一生物医疗科技有限公司 可降解生物复合止血膜及其制备方法
KR20180121493A (ko) 2015-12-29 2018-11-07 갈데르마 소시에떼아노님 바이오폴리머의 탈아세틸화 방법
EP3252082A1 (de) * 2016-05-31 2017-12-06 Galderma S.A. Verfahren zur deacetylierung von biopolymeren
WO2017192753A1 (en) 2016-05-03 2017-11-09 Bvw Holding Ag Multiphase gel
PT3623390T (pt) 2016-05-31 2023-10-27 Galderma Sa Reticulador de hidrato de carbono
CN106693067A (zh) * 2016-07-15 2017-05-24 温州生物材料与工程研究所 一种自愈合无模板多孔支架的制备
WO2018039496A1 (en) 2016-08-24 2018-03-01 Allergan, Inc. Co-crosslinked hyaluronic acid-silk fibroin hydrogels for improving tissue graft viability and for soft tissue augmentation
KR101969446B1 (ko) * 2017-06-30 2019-04-16 한양대학교 산학협력단 히알루론산 기반 보습 소재
CN109602686A (zh) * 2019-02-02 2019-04-12 西安力邦制药有限公司 一种水凝胶化妆品组合物及其制备方法
CN109939260A (zh) * 2019-03-01 2019-06-28 昆明理工大学 一种医用壳聚糖/透明质酸钠偶联水凝胶的制备方法
CN110773241A (zh) * 2019-09-16 2020-02-11 浙江工业大学 一种耐有机溶剂阳离子交换膜的制备方法
CN110773240A (zh) * 2019-09-16 2020-02-11 浙江工业大学 一种兼具耐高温及耐有机溶剂阳离子交换膜的制备方法
EP4069753A1 (de) 2019-12-02 2022-10-12 Galderma Holding SA Ästhetische zusammensetzungen mit hohem molekulargewicht
CN111249519A (zh) * 2020-01-17 2020-06-09 浙江理工大学 一种皮肤创口粘合修复材料及其制备方法、应用
CN111732675A (zh) * 2020-08-18 2020-10-02 山东华熙海御生物医药有限公司 透明质酸-氨基葡萄糖接枝共聚物、制法及其应用
CN114716581A (zh) * 2022-03-25 2022-07-08 常州百瑞吉生物医药有限公司 一种多重改性透明质酸衍生物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760200A (en) * 1987-09-18 1998-06-02 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
WO2000001733A1 (en) * 1998-07-06 2000-01-13 Fidia Advanced Biopolymers S.R.L. Amides of hyaluronic acid and the derivatives thereof and a process for their preparation
WO2000027887A2 (en) * 1998-11-11 2000-05-18 Aquisitio S.P.A. Cross-linked hyaluronic acids and medical uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE456346B (sv) 1984-07-23 1988-09-26 Pharmacia Ab Gel for att forhindra adhesion mellan kroppsvevnader och sett for dess framstellning
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US5017229A (en) 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US4937270A (en) * 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
JPH0675680B2 (ja) * 1988-08-09 1994-09-28 富士紡績株式会社 陰イオン交換能を有するキトサン成形物の製造法
US5708152A (en) * 1992-03-27 1998-01-13 Ciba Specialty Chemicals Corporation N-substituted chitosan derivatives in a process for their preparation
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
US5597811A (en) * 1995-04-10 1997-01-28 Amerchol Corporation Oxirane carboxylic acid derivatives of polyglucosamines
KR19990049107A (ko) * 1997-12-11 1999-07-05 이영무 고분자 전해질 복합체 스폰지의 제조방법
IT1303738B1 (it) * 1998-11-11 2001-02-23 Aquisitio S P A Processo di reticolazione di polisaccaridi carbossilati.
JP4187917B2 (ja) * 2000-09-08 2008-11-26 独立行政法人科学技術振興機構 組織再生マトリックス用グリコサミノグリカン−コラーゲン複合体の製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760200A (en) * 1987-09-18 1998-06-02 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
WO2000001733A1 (en) * 1998-07-06 2000-01-13 Fidia Advanced Biopolymers S.R.L. Amides of hyaluronic acid and the derivatives thereof and a process for their preparation
WO2000027887A2 (en) * 1998-11-11 2000-05-18 Aquisitio S.P.A. Cross-linked hyaluronic acids and medical uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0230990A1 *

Also Published As

Publication number Publication date
US20040014960A1 (en) 2004-01-22
BR0114561A (pt) 2003-08-26
JP4230767B2 (ja) 2009-02-25
AU2001294320A1 (en) 2002-04-22
JP2004511588A (ja) 2004-04-15
CN1290869C (zh) 2006-12-20
KR100375299B1 (ko) 2003-03-10
US6903199B2 (en) 2005-06-07
WO2002030990A1 (en) 2002-04-18
EP1328552B1 (de) 2012-12-12
EP1328552A1 (de) 2003-07-23
KR20020028435A (ko) 2002-04-17
CN1468262A (zh) 2004-01-14

Similar Documents

Publication Publication Date Title
US6903199B2 (en) Crosslinked amide derivatives of hyaluronic acid and manufacturing method thereof
EP1144459B2 (de) Vernetzte hyaluronsäure und ihre medizinischen verwendungen
FI94357C (fi) Menetelmä veteen liukenemattomien hyaluronihappogeelien ja -kalvojen valmistamiseksi
KR100507545B1 (ko) 히알루론산 유도체 및 그의 제조방법
JP4791921B2 (ja) ヒアルロン酸アミドおよびそれらの誘導体、並びにそれらの製造法
JP3399526B2 (ja) ヒアルロン酸の非水溶性誘導体
Yan et al. Fabrication of injectable hydrogels based on poly (l-glutamic acid) and chitosan
WO2004020473A1 (en) Microbeads of natural polysaccharide and hyaluronic acid and processes for preparing the same
JP3121019B2 (ja) 水溶性を増大させるための繰返しポリマーの化学修飾
US20060166928A1 (en) Hyaluronic acid derivative gel and method for preparing the same
JP2002529549A (ja) カルボキシル化多糖の架橋方法
US20050222405A1 (en) Polysaccharide containing phosphorylcholine group and process for producing the same
US10968286B2 (en) Site-selective modification of polysaccharides and applications thereof
CN108619085A (zh) 一类超分子水凝胶纳米材料及凝胶因子前体及其制法
WO2011089267A1 (en) Silylated biomolecules
RU2713295C2 (ru) Способ сшивания полисахаридов при помощи фотоудаляемых защитных групп
Pavinatto et al. Chemically modified chitosan derivatives
KR100466480B1 (ko) 감마폴리글루탐산과 키토산의 생분해성 공중합체 및 이를이용하여 제조된 필름

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030409

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050927

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61L 27/20 B

Ipc: 7A 61L 31/04 B

Ipc: 7A 61L 27/50 B

Ipc: 7C 08B 37/00 A

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 588296

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121215

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: RENTSCH PARTNER AG, CH

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60147488

Country of ref document: DE

Effective date: 20130207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121212

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121212

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130323

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20121212

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 588296

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130313

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121212

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121212

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121212

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130412

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121212

26N No opposition filed

Effective date: 20130913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121212

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60147488

Country of ref document: DE

Effective date: 20130913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121212

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20131010

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131031

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131031

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131010

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60147488

Country of ref document: DE

Effective date: 20140501

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140501

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131010